Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 1999;84:1258-1267

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khachigian, L. M.
Right arrow Articles by Johnson, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khachigian, L. M.
Right arrow Articles by Johnson, A. C.
Related Collections
Right arrow Genomics
Right arrow Growth factors/cytokines
Right arrow Other Vascular biology
(Circulation Research. 1999;84:1258-1267.)
© 1999 American Heart Association, Inc.

Original Contributions

GC Factor 2 Represses Platelet-Derived Growth Factor A-Chain Gene Transcription and Is Itself Induced by Arterial Injury

Levon M. Khachigian, Fernando S. Santiago, Louise A. Rafty, Onza L.-W. Chan, Gabrielle J. Delbridge, Alex Bobik, Tucker Collins, Alfred C. Johnson

From the Centre for Thrombosis and Vascular Research (L.M.K., F.S.S., L.A.R., O.L.W.C., G.J.D.), The University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, Australia; Baker Medical Research Institute (A.B.), Prahran, Australia; Vascular Research Division (T.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; and Laboratory of Molecular Biology (A.C.J.), Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Correspondence to Levon M. Khachigian, PhD, Centre for Thrombosis and Vascular Research, School of Pathology, The University of New South Wales, Sydney NSW 2052, Australia. E-mail L.Khachigian{at}unsw.edu.au


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Abstract—Platelet-derived growth factor (PDGF) is a mitogen and chemoattractant for a wide variety of cell types. The genes encoding PDGF A chain (PDGF-A) and PDGF B chain (PDGF-B) reside on separate chromosomes and are independently regulated at the level of transcription. Regulatory events underlying inducible PDGF-A expression have been the focus of much investigation. However, mechanisms that inhibit transcription of this gene are not well understood. In this study, we report the capacity of a newly cloned DNA binding factor, GC factor 2 (GCF2), to repress expression driven by the human PDGF-A promoter. 5' Deletion and transient cotransfection analysis in vascular endothelial cells revealed that GCF2 repression is mediated by a nucleotide region located in the proximal region of the PDGF-A promoter. Electrophoretic mobility shift assays demonstrate that GCF2 binds to this region in a specific and dose-dependent manner. Interestingly, the site bound by GCF2 overlaps those for specificity protein-1 (Sp1) and early growth response factor-1 (Egr-1), zinc finger transcription factors that direct basal and inducible expression of the PDGF-A gene. Gel shift experiments revealed that GCF2 competes with these factors for interaction with the PDGF-A promoter. Overexpression of GCF2 suppressed endogenous PDGF-A expression in vascular endothelial cells and smooth muscle cells. GCF2 was induced on mechanical injury of cells in culture as well as after balloon injury of the rat carotid artery wall. Time course studies revealed the sustained induction of GCF2 after injury while PDGF-A levels sharply returned to baseline. Smooth muscle cell proliferation was inhibited by GCF2, an effect reversed by the addition of exogenous PDGF-AA. These findings demonstrate negative regulation of PDGF-A expression by GCF2. This is the first report of the induction of an endogenous transcriptional repressor in the rat vessel wall.


Key Words: GC factor 2 • platelet-derived growth factor-A • DNA binding protein • transcription • injury


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Platelet-derived growth factor (PDGF) comprises a family of cationic polypeptides with mitogenic and chemoattractant activity. PDGF consists of an A chain (PDGF-A) or B chain (PDGF-B) held in homodimeric or heterodimeric configuration by disulfide linkages. These isoforms (AA, BB, and AB) are glycoproteins with an approximate molecular mass of 26 to 30 kDa. The PDGF-A– and PDGF-B–chain genes reside on different chromosomes, and their expression is independently regulated. The A-chain gene resides on chromosome 7 (7pter-7q22) and contains {approx}24 kb of DNA spanning 7 exons.1 A single transcriptional start site is located 36 bp downstream of the TATA box.1 The promoter is highly rich in guanines and cytosines (G+C) and contains functional binding sites for a number of zinc finger transcription factors including specificity protein-1 (Sp1),2 Sp3,3 early growth response factor-1 (Egr-1)2 and the Wilms tumor repressor gene product WT-1.4 5 These sites occur in the proximal region of the promoter hypersensitive to cleavage by S1 nuclease.6 Sp1 is required for basal expression of PDGF-A in both vascular endothelial cells and smooth muscle cells.2 3 PDGF-A promoter-dependent expression is induced in endothelial cells exposed to a variety of agonists and pathophysiological conditions, including fluid shear stress,7 phorbol ester,2 and (acidic) fibroblast growth factor-18 and involves displacement of Sp1 from the promoter by Egr-1. Egr-1 binds to the PDGF-A promoter, as well as the PDGF-B promoter9 within minutes of exposure to agonist.

In contrast to inducible PDGF transcription, mechanisms downregulating PDGF expression are not well characterized. Transcriptional repressors inhibit gene expression by one of at least two general mechanisms.10 First, passive repression, involves nuclear proteins competing with positive transcriptional regulators for common binding sites. These repressors may also modulate promoter activity by interacting with transcriptional activators themselves. Activity of the PDGF-B promoter can be repressed by the zinc finger protein ZNF174, cloned originally from a human fetal library, likely by passive means.11 Second, active repression, involves the intrinsic inhibitory activity of the repressor. WT-1, an active repressor, can inhibit PDGF-A promoter activity as well as expression driven from the promoters of a large number of other genes. These include insulin-like growth factor type II,12 transforming growth factor-ß1,13 colony-stimulating factor-1,14 and insulin-like growth factor-1 receptor.15 Despite the capacity of WT-1 to repress reporter expression driven by multiple growth factor promoters, the relevance of WT-1 repression to the regulation of the authentic gene has not been established. Additionally, the limited pattern of WT-1 expression and the transient nature of growth factor induction suggests that other repressors may exist with the ability to negatively regulate growth factor gene expression.

GCF is a transcriptional repressor so termed because of its preference for G+C-rich elements in DNA. GCF is a 91-kDa protein that interacts and downregulates expression driven by the epidermal growth factor receptor (EGFR) promoter, which lacks TATA and CAAT motifs.16 A second member of the GCF family, GCF2, was recently isolated from an ovarian carcinoma cDNA library.17 GCF2 shares homology with GCF in a 309-bp region located at positions 1382-1690 within the 2256 nucleotides constituting the GCF2 open reading frame.17 Native GCF2 mRNA is 4.2 kb in length and encodes an acidic protein (pI of 4.4) with relative molecular mass of 83 kDa.17 GCF2 expression in epidermoid carcinoma cells is decreased by phorbol ester treatment before increased EGFR expression.17 In addition, nerve growth factor treatment of PC12 cells results in elevated GCF2 expression and decreased levels of EGFR.18 In the present study, we determined whether GCF2 has the capacity to bind to the PDGF-A promoter and modulate its activity. We demonstrate that GCF2 interacts with the promoter in a specific and dose-dependent manner and competes with transcription factors directing expression of the gene for overlapping binding sites. GCF2 represses PDGF-A promoter-dependent expression and can inhibit the expression of the endogenous gene itself. In addition, we provide evidence for an inverse relationship between the repressor and the growth factor in the artery wall after mechanical injury.


*    Materials and Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Materials and Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Cell Culture
Bovine aortic endothelial cells were purchased from Cell Applications, Inc, and grown in DMEM (pH 7.4) containing 10% FBS, 50 µg/mL streptomycin, and 50 IU/mL penicillin at 37°C in a humidified atmosphere of 5% CO2. Rat aortic smooth muscle cells were obtained from Cell Applications, Inc, and grown in Waymouth's medium (pH 7.4) containing 10% FBS and antibiotics. Cells were routinely passaged with trypsin/EDTA and not used in experiments beyond passage 6.

Transient Transfection Analysis and Chloramphenicol Acetyltransferase (CAT) Assay
Endothelial cells in 100-mm-diameter dishes at 70% confluency were transfected with the indicated amounts of cesium chloride–purified plasmid DNA using a modification of a calcium phosphate precipitation method.19 After transfection, the cells were incubated overnight in an atmosphere of 3% CO2, washed twice with PBS (pH 7.4) and incubated for an additional 24 hours at 5% CO2. Cell lysates were assessed for CAT activity as previously described.2 Conditioned medium was sampled at the time the cells were harvested and assayed for human growth hormone (Bioclone) to correct for transfection efficiency. Total protein concentration in the lysates was assessed using a modified Bradford assay (Bio-Rad) and used to normalize transfection data.

Electrophoretic Mobility Shift Assay (EMSA)
Binding reactions for gel shift assays were performed in 20 µL of 10 mmol/L Tris-HCl, 50 mmol/L MgCl2, 1 mmol/L EDTA, 1 mmol/L DTT, 5% glycerol, 1 mmol/L PMSF, 0.75 µg salmon sperm DNA, 5% sucrose, 0.75 µg poly dI-dC, 10 µg of BSA, 32P-labeled oligonucleotide probe (150 000 cpm), and 1.5, 3, or 6 µg of in vitro transcribed/translated GCF2 protein.17 The reaction was incubated for 35 minutes at 22°C. In competition gel shifts, 6 µg of nuclear extract was prepared as described2 and combined with 6 µg of GCF2 protein. As a control, an equal amount of BSA protein was substituted for GCF2. Bound complexes were separated from free probe by loading the samples onto a 5% nondenaturing polyacrylamide gel (PAGE) and electrophoresing at 200 V for 2 to 3 hours. The gels were dried and subjected to autoradiography overnight at -80°C.

Northern Blot Analysis
Endothelial cells or smooth muscle cells were grown to 70% confluency in 100-mm-diameter Petri dishes and transfected with 10 µg pcDNA3 or GCF2-pcDNA3 using FuGENE6 reagent (Boehringer Mannheim) at a FuGENE6:DNA ratio of 3:1 (vol:µg), per the manufacturer's instructions. After 24 hours, total RNA was extracted with TRIzol reagent (Life Technologies), and 20 µg of each sample was resolved by electrophoresis on 1% formaldehyde/agarose/MOPS gels. RNA was transferred overnight onto Hybond nylon membranes before hybridization with a 32P-labeled 260-bp fragment of PDGF-A cDNA in ExpressHyb (Clontech). Vacuum-dried gels were autoradiographed for 1 week at -80°C, then stripped and reprobed with a 32P-labeled 1.1-kb fragment of GCF2 cDNA, and later with a 32P-labeled fragment of ß-actin cDNA followed by reexposure.

Injury and Western Blot Analysis
Endothelial cells or smooth muscle cells were rendered growth-quiescent by incubation overnight in medium containing 1% or 0.1% FBS, respectively. The cells were injured by repeated scraping with a sterile stainless steel comb and solubilized in RIPA buffer. Extracts were resolved by 10% SDS-PAGE and transferred to nylon membranes by electrophoretic blotting. Nonspecific binding sites on the membrane were blocked with nonfat skim milk before probing with affinity-purified rabbit polyclonal antibodies to PDGF-A (Genzyme) or GCF2. This was followed by chemiluminescent detection using HRP-linked swine anti-rabbit secondary antiserum (NEN-DuPont).

Assays of Cell Proliferation
Cells were seeded into 96-well titer plates (Nunc-InterMed) at 2500 cells per well and allowed to grow for 48 hours in complete medium. The cells were transfected with 1 µg of the indicated plasmid in complete growth medium using FuGENE6 (Boehringer Mannheim) in accordance with manufacturer's instructions. At the time of transfection, and again after 24 hours, the cells were rinsed with PBS (pH 7.4) and trypsinized, and the suspension was quantitated using an automated particle counter (Coulter Electronics).

Rat Carotid Artery Injury and Immunohistochemical Analysis
Sprague-Dawley rats (400 g) were obtained from the Biology Research Unit, Baker Medical Research Institute, Melbourne, Australia. Left common carotid arteries of anesthetized rats (ketamine 80 mg/kg; xylene 10 mg/kg) were subjected to balloon catheter injury using a 2F Fogarty catheter as previously described.20 Briefly, the saline-inflated balloon catheter was passed along the length of the common carotid four times. Various times after injury (0, 4 hours, 6 hours, 24 hours, and 10 days), rats were anesthetized with sodium pentobarbitone (100 mg/kg). The vessels were perfused with saline and gently dissected free of surrounding tissue, frozen in OCT compound (Tissue-Tek), and sectioned (5 µm). Sections were fixed in 4% formalin for 2 minutes, then absolute ethanol for 10 minutes. For immunohistochemical analysis,21 sections were incubated with affinity-purified rabbit polyclonal IgG raised against PDGF-AA (1:100) (Genzyme) or in vitro transcribed/translated GCF2 (1:200).17 Secondary detection was performed using the avidin-biotin complex (ABC) kit.22 Deendothelialization was confirmed by vital staining with Evans blue (60 mg/kg IV). All surgical procedures were approved by the Baker Medical Research Institute and Alfred Hospital Animal Experimentation Committee.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 *Results
down arrowDiscussion
 down arrowReferences
 
GCF2 Represses PDGF-A Promoter-Dependent Expression
To determine whether GCF2 can influence expression driven by the PDGF-A promoter, we transfected endothelial cells with a GCF2 expression vector driven by the cytomegaloviral (CMV) promoter (construct GCF2-pcDNA3), together with a CAT reporter construct, {Delta}Sac, bearing 643 bp of PDGF-A promoter sequence. CAT activity was normalized for transfection efficiency after assessment of human growth hormone levels secreted into the culture medium. Overexpression of GCF2 in this cotransfection setting strongly inhibited reporter expression driven by the PDGF-A promoter (Figure 1Down). GCF2 repression of PDGF-A promoter-driven CAT activity was also observed in rat vascular smooth muscle cells (data not shown). In contrast, overexpression of a transcriptional activator of PDGF-A, Egr-1, with the same backbone (pcDNA3) stimulated CAT activity 2-fold (Figure 1Down).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 1. GCF2 represses the activity of the PDGF-A promoter. Endothelial cells were transfected with 15 µg of PDGF-A promoter CAT construct {Delta}Sac and 5 µg of pcDNA3, GCF2-pcDNA3, or Egr-1-pcDNA3 as indicated. The cells were cotransfected with 2 µg of pTKGH to correct for transfection efficiency. CAT reporter activity was normalized to levels of growth hormone (GH) secreted into the conditioned medium. Error bars represent SEM from at least 2 independent determinations.

Repression by GCF2 Is Mediated by Nucleotide Elements Located in the Proximal Region of the PDGF-A Promoter
GCF2 binds preferentially to nucleotide sequences rich in guanines and cytosines.17 The proximal region of the PDGF-A promoter is intensely G+C-rich.1 We hypothesized that GCF2 repression of the PDGF-A promoter may involve elements located in the proximal region. Transient cotransfection experiments revealed that expression driven by construct f28, which contains 71 bp of PDGF-A promoter sequence,2 was inhibited by GCF2 coexpression (Figure 2Down). However, when GCF2-pcDNA3 was cotransfected with construct f36, which bears 55 bp of promoter sequence,2 repression by GCF2 was no longer observed (Figure 2Down). These findings suggest that GCF2 repression of the PDGF-A promoter is mediated by nucleotide elements located between the 5' promoter end points of f28 and f36. The GCF2 binding site in the epidermal growth factor receptor promoter has a core binding sequence of 5'-AGC CCC CGG CG-3' (or 5'-CG CCG GGG GCT-3').17 The nucleotide sequence between the f28 and f36 5' end points bears the 5'-CGG GGG C-3' motif (Figure 2Down). Separate experiments revealed that a CAT reporter construct driven by 153 bp of the PDGF-B promoter,23 which does not bear the GCF2 core binding sequence, was unaffected by cotransfection with GCF2-pcDNA3 (data not shown).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. GCF2 repression of the PDGF-A promoter is mediated by a G+C-rich sequence in the proximal region of the promoter. Cells were transfected with 15 µg of PDGF-A promoter CAT construct f28 or f36 and either 5 µg of pcDNA3 or GCF2-pcDNA3. The cells were cotransfected with 2 µg of pTKGH to correct for transfection efficiency. CAT reporter activity was normalized to levels of growth hormone in the supernatant. Error bars represent SEM from at least 2 independent determinations. A schematic representation of f28 and f36 is also provided.2

GCF2 Interacts With Proximal PDGF-A Promoter
To determine whether GCF2 binds directly to the PDGF-A promoter, we incubated in vitro transcribed/translated GCF2 with a 32P-labeled probe, Oligo A, whose sequence spans the 5' end points of f28 and f36, and resolved the adducts by electrophoresis under nondenaturing conditions. GCF2 bound to the oligonucleotide in a dose-dependent manner as two distinct nucleoprotein complexes (Figure 3ADown). The upper and more intense complex represents dimeric GCF2, whereas the lower complex is the monomeric form.17 Neither complex was observed when an oligonucleotide bearing an unrelated sequence, 32P-LKmdc, was substituted for 32P-Oligo A (Figure 3ADown). Furthermore, neither complex formed when 32P-Oligo Am was substituted for 32P-Oligo A (Figure 3ADown). Oligo Am was generated by altering the 5'-CGG GGG C-3' repeated motif in Oligo A by insertion of additional guanines (5'-CGG GGG gC-3') thus disrupting the promoter sequence. When wild-type 32P-Oligo A was incubated with GCF2{Delta}510, an in vitro transcribed/translated form of GCF2 that carries a deletion in its DNA binding domain,17 nucleoprotein complex formation was no longer observed (Figure 3BDown). Additional experiments revealed that wild-type GCF2 failed to interact with a 32P-labeled G+C-rich RNA oligomer composed of 23 bases (data not shown). Taken together, these findings demonstrate that GCF2 interacts with the proximal PDGF-A promoter in a dose-dependent and specific manner.



View larger version (42K):
[in this window]
[in a new window]
  		Figure 3. GCF2 interacts with the proximal PDGF-A promoter. A, Specific and dose-dependent interaction of GCF2. EMSA was performed with in vitro transcribed/translated GCF2 protein and the 32P-labeled oligonucleotides indicated in the figure as described in Materials and Methods. B, DNA binding domain of GCF2 is critical for interaction with proximal PDGF-A promoter. In vitro transcribed/translated GCF2{Delta}510 lacks the complete 309-bp DNA binding domain of GCF2 (1382-1690).17 Arrows indicate monomeric and dimeric forms of bound GCF2.17 The nucleotide sequence of Oligo A is 5'-GGG GGG GGC GGG GGC GGG GGC GGG GGA GG-3' and LKmdc is 5'-GCT GTC TCC ACC CAT TGT TCG CAC TCT-3'; Oligo Am is 5'-GGG GGG GGC GgG GGG CgG GGG GCg GGG GGA GG-3' (sense strand shown; bases indicated in lowercase denote insertions).

Competition Between Several Zinc Finger Binding Proteins and GCF2 for Binding Sites in the Proximal PDGF-A Promoter
The preceding findings demonstrate the capacity of GCF2 to bind to the PDGF-A promoter and inhibit promoter-dependent reporter gene expression. We next addressed the question of the mechanism underlying GCF2 repression. Previous studies by our group have shown that a number of zinc finger transcription factors interact with the GCF2 binding site and mediate basal and inducible expression of the PDGF-A gene. These nuclear factors include Sp1 and Egr-1.2 We explored the possibility that GCF2 competes with these factors for binding to the PDGF-A promoter. Endothelial extracts were incubated with 32P-Oligo A in the absence or presence of GCF2 or a corresponding amount of BSA, before resolution of 32P-labeled nucleoprotein complexes by electrophoresis. This produced the characteristic profile of 32P-labeled nucleoproteins composed of Sp1, Egr-1, Sp3, and other nuclear proteins2 3 24 (Figure 4Down). Inclusion of GCF2 in the binding mixture markedly attenuated the intensity of the Sp1, Egr-1, and Sp3 complexes, among other complexes (Figure 4Down). In contrast, these complexes were unaffected by substitution of GCF2 with an identical amount of BSA (Figure 4Down). Thus, GCF2 competes with these positive regulatory transcription factors for overlapping binding sites in the PDGF-A promoter.



View larger version (63K):
[in this window]
[in a new window]
  		Figure 4. GCF2 competes with several zinc finger transcription factors for binding to the proximal PDGF-A promoter. Nuclear extracts of endothelial cells in log phase were incubated with 32P-Oligo A, in the absence or presence of 1 µg in vitro transcribed/translated GCF2 or BSA before resolution by electrophoresis and autoradiography.

Mechanical Injury Stimulates PDGF-A and GCF2 Expression In Vitro
To determine the potential pathophysiological relevance of the above findings to vascular disorders, we examined the relationship between GCF2 and PDGF-A expression in an in vitro model of cell injury. Endothelial cell monolayers were scraped repeatedly with a sterile stainless steel comb,3 9 and lysates were assessed for levels of PDGF-A. PDGF-A was weakly expressed in unmanipulated endothelial cells (Figure 5ADown). However, within 4 hours of injury, PDGF-A levels increased 3-fold (Figure 5ADown, open bars), consistent with a previous report of inducible PDGF-A expression in aortic endothelium within 4 hours of mechanical injury.25 By 8 hours, PDGF-A levels increased almost 10-fold and returned to preinjury levels by 12 hours (Figure 5ADown).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 5. Mechanical injury induces endothelial expression of GCF2 and PDGF-A. Vascular endothelial cells were grown to confluence and rendered quiescent by incubation in 1% FBS for 24 hours. Monolayers were injured by repeated scraping with a sterile stainless steel comb. Cell lysates were resolved by SDS-PAGE, before transfer to nylon membranes and Western immunoblot analysis with polyclonal antibodies raised against PDGF-AA (A) or GCF2 (B). After chemiluminescent detection, bands were quantitated by scanning densitometry. Open bars denote PDGF-A; closed bars, GCF2. Gels were stained with Coomassie blue to demonstrate equal protein loading.

We next determined whether GCF2 was induced by injury in this model. GCF2 is basally expressed in resting cells, and levels increased 4 hours and 8 hours after injury (Figure 5BUp). By 12 hours, however, GCF2 levels increased 3-fold (Figure 5BUp, closed bars), at which time PDGF-A levels had returned to background (Figure 5AUp). The inverse temporal correlation between GCF2 and PDGF-A after peak expression of the growth factor in this model suggests a regulatory role for GCF2 in the expression of PDGF-A after injury.

Mechanical Injury of Arteries In Vivo Stimulates GCF2 Expression
To provide evidence for a similar relationship between these genes in the artery wall, levels of PDGF-A and GCF2 were assessed in the arterial media by immunohistochemical analysis various times after balloon catheter injury of the rat carotid20 . PDGF-A antigen was weakly, if at all, expressed in the unmanipulated artery wall (Figure 6ADown). Within 4 hours of injury, PDGF-A was clearly expressed in the media (Figure 6BDown, arrow) as previously reported.26 27 Expression was only transient, because PDGF-A immunoreactivity was not detected at 6 hours (Figure 6CDown) or after 10 days (Figure 6DDown), when a significant neointima had formed, a hallmark of this model.20



View larger version (56K):
[in this window]
[in a new window]
  		Figure 6. Induction of PDGF-A expression by mechanical injury to the rat carotid artery wall. Immunohistochemistry was performed on 5-µm cross sections of balloon-injured rat carotid arteries using affinity-purified rabbit polyclonal antibodies raised against PDGF-A. A, Uninjured artery. B, Four hours after injury. C, Six hours after injury. D, Ten days after injury. E, Four hours after injury, without PDGF-A IgG (primary) antibody but with secondary (goat anti-rabbit IgG) antibody and components of ABC kit. Brown staining (indicated by arrow) indicates specific signal. Sections were counterstained with hematoxylin to identify cell nuclei. Magnification x200.

In contrast to PDGF-A, GCF2 was basally expressed in normal artery wall (Figure 7ADown). Injury dramatically increased GCF2 expression in the media within 4 hours (Figure 7BDown). Unlike PDGF-A, GCF2 levels remained elevated over the next 18 hours (Figures 7BDown through 7DDown). Indeed, intense GCF2 expression even 24 hours after injury (Figure 7DDown) contrasts dramatically with the rapid decline in PDGF-A levels between 4 and 6 hours (Figures 6BUp through 6CUp). Ten days after injury, GCF2 was still expressed at levels comparable to those in the uninjured vessel wall (compare Figure 7EDown to 7ADown). Staining for both GCF2 and PDGF-A was specific, because neither the secondary antibody nor components of the immunohistochemical detection system produced positive staining in the absence of primary antibody. These findings provide a spatial and inverse temporal correlation between GCF2 and PDGF-A after peak PDGF-A expression after injury to the vessel wall.



View larger version (46K):
[in this window]
[in a new window]
  		Figure 7. Sustained activation of GCF2 by injury. Immunohistochemical analysis was performed on 5-µm cross sections of balloon-injured rat carotid arteries using affinity-purified rabbit polyclonal antibodies raised against in vitro transcribed/translated GCF2. A, Uninjured artery. B, Four hours after injury. C, Six hours after injury. D, Twenty-four hours after injury. E, Ten days after injury. F, Uninjured artery without GCF2 (primary) antibody but with secondary (goat anti rabbit IgG) antibody and components of ABC kit. Brown staining indicates specific signal. The blue stain is a consequence of Evans blue infusion before sacrifice. Sections were counterstained with hematoxylin to identify cell nuclei. Magnification x200.

We performed Western blot analysis for GCF2 protein with lysates of cultured smooth muscle cells prepared various times after mechanical injury to verify findings from immunostaining of the injured artery wall (Figure 7Up). GCF2 protein was inducibly expressed within 1 hour of injury; levels continued to increase at 4 hours and 6 hours (Figure 8Down). These data are consistent with the temporal pattern of inducible GCF2 protein expression in medial smooth muscle cells of the injured vessel wall (Figure 7Up).



View larger version (41K):
[in this window]
[in a new window]
  		Figure 8. GCF2 protein is inducibly expressed by cultured smooth muscle cells after mechanical injury. Quiescent confluent smooth muscle cells were injured by repeated scraping, and lysates were resolved by SDS-PAGE. Western immunoblot analysis was performed with GCF2 antibodies. Bands were visualized by chemiluminescent detection. Gels were stained with Coomassie blue to demonstrate equal protein loading.

Overexpression of GCF2 Attenuates Endogenous PDGF-A Expression
The temporal relationship between GCF2 and PDGF-A in these models suggests that GCF2 may downregulate the expression of endogenous PDGF-A. Because our earlier studies used PDGF-A promoter reporter constructs in an overexpression setting, we performed Northern blot analysis using total RNA of two different vascular cell types 24 hours after transfection with GCF2-pcDNA3 or the backbone alone. Because this approach requires high transfection efficiency, we used a lipid-based formulation that enabled transfection of virtually the entire cell population (data not shown). PDGF-A mRNA, as expected, was expressed at higher levels in smooth muscle cells than endothelial cells28 (Figure 9ADown). In both cell types, however, endogenous PDGF-A expression was completely inhibited by GCF2-pcDNA3 transfection (Figure 9ADown). To confirm the expression of GCF2 on transfection of this plasmid, the blot was stripped and reprobed with a 32P-labeled GCF2 cDNA fragment. Strong hybridization was observed in both cell types with an mRNA species of {approx}2.3 kb17 (Figure 9ADown), consistent with the size of GCF2 cDNA insert present in the vector. In contrast, ß-actin mRNA levels were unaffected by GCF2 overexpression (Figure 9ADown). These findings demonstrate the capacity of GCF2 to suppress native PDGF-A expression in two vascular cell types. To demonstrate expression of GCF2 protein, as well as mRNA, after transfection with GCF2-pcDNA3, we prepared nuclear extracts of cells transfected with this construct as well as the backbone alone. EMSA, using these extracts together with 32P-labeled Oligo A, indicates that in vivo expressed GCF2 protein can interact with its binding site in the proximal PDGF-A promoter (Figure 9BDown).



View larger version (35K):
[in this window]
[in a new window]
  		Figure 9. Overexpression of GCF2 represses PDGF-A mRNA expression. A, Total RNA (20 µg) from endothelial cells (ECs) or smooth muscle cells (SMCs) transfected with 10 µg pcDNA3 or GCF2-pcDNA3 using FuGENE6 was resolved by electrophoresis, before transfer to a nylon membrane and hybridization with 32P-labeled fragment of PDGF-A cDNA. After autoradiography, the blot was stripped and reprobed with a 32P-labeled fragment of GCF2 cDNA. After a second exposure, the blot was stripped and reprobed with a 32P-labeled fragment of ß-actin cDNA. B, Nuclear extracts of endothelial cells transfected with 10 µg pcDNA3 or GCF2-pcDNA3 using FuGENE6 were incubated with 32P-Oligo A, and the products were resolved by electrophoresis and subsequent autoradiography. The filled arrow indicates GCF2 binding activity; empty arrow, complex formation by extract proteins; and NE, nuclear extract. Free label was run off the gel for improved resolution.

Overexpression of GCF2 Inhibits Smooth Muscle Cell Replication
Finally, we determined whether exogenous GCF2 had the ability to influence cell proliferation. Endothelial cells or smooth muscle cells transfected with either GCF2-pcDNA3 or pcDNA3 were resuspended by trypsinization and quantitated. Endothelial cell replication after 24 hours was unaffected by GCF2 transfection (Figure 10ADown). However, proliferation was inhibited in smooth muscle cells transfected with GCF2 (Figure 10BDown). Cell growth in this group 24 hours after transfection was 37% less than the population of cells transfected with pcDNA3 alone (Figure 10BDown). In contrast, proliferation of smooth muscle cells transfected with construct GCF2{Delta}428-pcDNA3, which lacks the GCF2 DNA binding domain, was not inhibited (Figure 10BDown). Interestingly, addition of PDGF-AA (30 ng/mL) rescued the cells from growth inhibition by GCF2 (Figure 10BDown). Morphological inspection of both cell types as well as trypan blue exclusion experiments revealed that differences in cell number were not due to cytotoxicity (data not shown). Therefore, although GCF2 suppressed endogenous PDGF-A expression in endothelial cells and smooth muscle cells, proliferation of only the latter cell type was attenuated as a consequence.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 10. GCF2 overexpression inhibits smooth muscle cell proliferation. ECs or SMCs were seeded in 96-well plates and left undisturbed for 48 hours. Cells were transfected with 1 µg pcDNA3, GCF2-pcDNA3, or GCF2{Delta}428-pcDNA3 using FuGENE6 in complete growth medium. Cell numbers per well were determined immediately before (day 0) or 24 hours after (day 1) the addition of serum (±PDGF-AA, 30 ng/mL), by quantitation of trypsinized suspensions by Coulter counter. Cell numbers were not assessed on subsequent days because of artifact introduced by contact inhibition. SFM (empty bars) indicates cells that were incubated with serum-free medium and exposed to the same amount of FuGENE6 as those transfected with DNA. Mean+SEM of 3 experiments performed in triplicate is shown. **P<0.0001 relative to the pcDNA3 value by Student paired t test.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 *Discussion
down arrowReferences
 
The specificity and efficiency with which eukaryotic genes are transcribed depend on specific, ordered interactions between transcription factors and cis-acting nucleotide elements in promoter regions. Models of inducible gene transcription involve the formation of 3-dimensional stereospecific enhancer complex composed of transcription factors that can bend DNA and components of the basal transcriptional machinery.29 30 Transactivation is also associated with alterations in chromatin structure.31 Repression is less well understood but is, nonetheless, an equally important aspect of transcriptional regulation. Here, we have described the ability of a newly cloned DNA binding factor, GCF2, to repress expression driven by the human PDGF-A promoter. Briefly, deletion and transient transfection analysis revealed that GCF2 repression is mediated at a region located between the 5' end points of PDGF-A promoter constructs f28 and f36. Gel shift experiments demonstrated that GCF2 interacts with this region of the promoter in a specific, dose-dependent manner and competes with activating transcription factors for overlapping binding sites. GCF2 is activated by mechanical injury in culture as well as in the artery wall. GCF2 can suppress endogenous PDGF-A expression in both endothelial cells and smooth muscle cells but attenuates proliferation in only the latter cell type.

The precise mechanism(s) with which GCF2 regulates PDGF-A transcription, or the transcription of other genes,17 is not clear. Active repressors, such as WT-1,32 and the human Kruppel-related factor, YY1,33 possess intrinsic repressing activity and the capacity to downregulate transcription through modular domains. On the other hand, passive repressors downregulate transcription by modulating the activity of positive regulatory factors. An example of a passive repressor is GCF, which may compete with transcription factors for common binding sites or interact directly with these proteins.16 In addition, NAB134 and NAB235 repress Egr-1–dependent transactivation by interacting with this zinc finger protein.36 GCF2 may also function as a passive transcriptional repressor, because it competes with Sp1 and Egr-1 for common binding sites in the PDGF-A promoter, and these transcription factors each activate PDGF-A transcription.2 3 Alternatively, or in addition, GCF2 may interact with DNA to destabilize bound factors or interact directly with factors to prevent binding or increase off rates. GCF2, like some repressors, may have the capacity to activate transcription under certain conditions. For example, whether WT-1 functions as a transcriptional repressor or activator seems to be dependent on physical interactions with p53.37 Although the present findings define a transcriptional regulatory role for GCF2, we cannot yet rule out the possibility that GCF2 controls gene expression by additional mechanisms, such as by regulation of mRNA stability. Detailed structural characterization of GCF2 should provide more detailed insights into the functional properties of this transcriptional repressor.

Many genes, whose products can influence chemotactic, mitogenic, adhesive, and thrombotic events are activated in response to mechanical injury (reviewed in References 38 through 4238 39 40 41 42 ). Several of these genes are under the transcriptional control of factors, such as c-Fos, c-Jun, c-Myc, c-Ets-1, nuclear factor-{kappa}B, and Egr-1, which are themselves activated by injury to the vessel wall.27 43 44 45 46 47 In contrast to positive regulatory factors, the present study is the first to report the inducible expression of an endogenous transcriptional repressor after mechanical injury of vascular cells in the rat model. Previously, Weir et al48 demonstrated downregulation of the growth arrest homeobox gene, gax, after balloon injury to the rat carotid. Recently, Aoyagi et al49 demonstrated p53 induction in the rabbit carotid artery wall after balloon denudation. Because GCF2 inhibits both PDGF-A promoter-dependent and endogenous PDGF-A mRNA expression, the repressor could influence the course of PDGF-A expression after injury. The capacity of GCF2 to inhibit smooth muscle cell replication without influencing endothelial cell growth is consistent with the notion of autocrine growth loop(s) involving PDGF in the former cell type.50 51 52 Smooth muscle cell responsiveness can be inhibited by substances such as suramin,53 antisense oligonucleotides directed at PDGF-A mRNA,54 and {alpha}2-macroglobulin,55 which block the PDGF ligand–PDGF receptor circuit. GCF2 may interfere with autocrine growth involving PDGF-A at the earliest stage in the cycle by inhibiting the production of the growth factor. That GCF2 inhibition of smooth muscle cell proliferation could be rescued by addition of exogenous PDGF-AA is consistent with an autocrine role for the PDGF A chain. Unlike smooth muscle cells, large vessel endothelial cells in culture do not express PDGF receptors.56 57 It is therefore not surprising that GCF2 could not inhibit the growth of cells lacking receptors for PDGF-A.

The promoters of many growth factor genes induced by injury, such as transforming growth factor-ß1, fibroblast growth factor-2, and PDGF-B, also contain G+C-rich elements that are bound by Sp1 and Egr-1.9 58 59 The capacity of GCF2 to compete with these and other zinc finger transcription factors indicates that negative regulation by GCF2 may not be confined to PDGF-A alone. Because Sp1 is required for COL1A1 and {alpha}2(I) collagen expression,60 61 and collagen accumulation in the neointima62 occurs when GCF2 levels have already returned to background (Figure 8Up), it is conceivable that GCF2 may also play a regulatory role in the composition of the matrix in the neointima.

The mechanisms underlying the induction of GCF2 itself, in the context of injury or any other stimulus, are not known. Elucidation of the genomic structure of GCF2 should provide valuable insights for the regulation of this gene. Future studies should determine whether positive regulatory factors such as Sp1 and Egr-1 can influence the inducible expression of this repressor and whether GCF2 can repress its own expression.


*    Acknowledgments
 
This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia, National Heart Foundation of Australia, and NSW Health Department. L.M.K. is a recipient of an R. Douglas Wright Fellowship from the NHMRC. T.C. is supported by NIH grant HL35716.

Received November 19, 1998; accepted February 24, 1999.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Bonthron DT, Morton CC, Orkin SH, Collins T. Platelet-derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing. Proc Natl Acad Sci U S A. 1988;85:1492–1496.[Abstract/Free Full Text]
  2. Khachigian LM, Williams AJ, Collins T. Interplay of Sp1 and Egr-1 in the proximal PDGF-A promoter in cultured vascular endothelial cells. J Biol Chem. 1995;270:27679–27686.[Abstract/Free Full Text]
  3. Silverman ES, Khachigian LM, Lindner V, Williams AJ, Collins T. Inducible PDGF A-chain transcription in vascular smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am J Physiol. 1997;42:H1415–H1426.
  4. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ III, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A. 1992;89:10984–10988.[Abstract/Free Full Text]
  5. Wang ZY, Madden SL, Deuel TF, Rauscher FJ III. The Wilms' tumor gene product, WT-1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem. 1992;267:21999–22002.[Abstract/Free Full Text]
  6. Wang Z, Lin X-H, Qiu Q-Q, Deuel TF. Modulation of transcription of the platelet-derived growth factor A-chain gene by a promoter region sensitive to S1 nuclease. J Biol Chem. 1992;267:17022–17031.[Abstract/Free Full Text]
  7. Khachigian LM, Anderson KA, Halnon NJ, Resnick N, Gimbrone MA Jr, Collins T. Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress response element in the PDGF A-chain promoter. Arterioscler Thromb Vasc Biol. 1997;17:2280–2286.[Abstract/Free Full Text]
  8. Delbridge GJ, Khachigian LM. FGF-1-induced PDGF A-chain gene expression in vascular endothelial cells involves transcriptional activation by Egr-1. Circ Res. 1997;81:282–288.[Abstract/Free Full Text]
  9. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science. 1996;271:1427–1431.[Abstract]
  10. Cowell IG. Repression versus activation in the control of gene transcription. Trends Biochem Sci. 1994;19:38–42.[Medline] [Order article via Infotrieve]
  11. Williams AJ, Khachigian LM, Shows T, Collins T. Isolation and characterization of a novel zinc-finger protein with transcriptional repressor activity. J Biol Chem. 1995;270:22143–22152.[Abstract/Free Full Text]
  12. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ III. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science. 1992;257:674–678.[Abstract/Free Full Text]
  13. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ III, Kim S-J. Repression of the transforming growth factor-ß1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol. 1994;8:595–602.[Abstract]
  14. Harrington MA, Konicek B, Song A, Xia X-L, Fredericks WJ, Rauscher FJ III. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem. 1993;268:21271–21275.[Abstract/Free Full Text]
  15. Werner H, Rauscher FJ III, Sukhatme VP, Drummond IA, Roberts CT Jr, LeRoith D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem. 1994;269:12577–12582.[Abstract/Free Full Text]
  16. Kageyama R, Pastan I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell. 1989;59:815–825.[Medline] [Order article via Infotrieve]
  17. Reed AL, Yamazaki H, Kaufman JD, Rubinstein Y, Murphy B, Johnson AC. Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor. J Biol Chem. 1998;273:21594–21602.[Abstract/Free Full Text]
  18. Shibutani M, Lazarovici P, Johnson AC, Katagiri Y, Guroff G. Transcriptional down-regulation of epidermal growth factor receptors by nerve growth factor treatment of PC12 cells. J Biol Chem. 1998;273:6878–6884.[Abstract/Free Full Text]
  19. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989.
  20. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. Lab Invest. 1983;49:327–333.[Medline] [Order article via Infotrieve]
  21. Ward MR, Agrotis A, Kanellakis P, Dilley R, Jennings G, Bobik A. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-ß isoforms and their receptors following arterial injury. Arterioscler Thromb Vasc Biol. 1997;17:2461–2470.[Abstract/Free Full Text]
  22. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577–580.[Abstract]
  23. Khachigian LM, Fries JWU, Benz MW, Bonthron DT, Collins T. Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells. J Biol Chem. 1994;269:22647–22656.[Abstract/Free Full Text]
  24. Rafty LA, Khachigian LM. Zinc finger transcription factors mediate high constitutive PDGF-B expression in smooth muscle cells derived from aortae of newborn rats. J Biol Chem. 1998;273:5758–5764.[Abstract/Free Full Text]
  25. Lindner V, Reidy MA. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium. Am J Pathol. 1995;146:1488–1497.[Abstract]
  26. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149–2158.[Abstract/Free Full Text]
  27. Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury: a putative mechanism for autocrine growth. Arterioscler Thromb. 1993;13:211–219.[Abstract/Free Full Text]
  28. Majesky MW, Benditt EP, Schwartz SM. Expression and developmental control of platelet-derived growth factor A-chain and B-chain/Sis genes in rat aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1988;85:1524–1528.[Abstract/Free Full Text]
  29. Tjian R, Maniatis T. Transcriptional activation: a complex puzzle with few easy pieces. Cell. 1994;77:5–8.[Medline] [Order article via Infotrieve]
  30. Carey M. The enhanceosome and transcriptional synergy. Cell. 1998;92:5–8.[Medline] [Order article via Infotrieve]
  31. Kornberg RD, Lorch Y. Interplay between chromatin structure and transcription. Curr Opin Cell Biol. 1995;7:371–375.[Medline] [Order article via Infotrieve]
  32. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science. 1991;252:1550–1553.
  33. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67:377–388.[Medline] [Order article via Infotrieve]
  34. Russo MW, Sevetson BR, Milbrandt J. Identification of NAB-1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci U S A. 1995;92:6873–6877.[Abstract/Free Full Text]
  35. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol. 1996;16:3545–3553.[Abstract]
  36. Svaren J, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, Milbrandt J. Novel mutants of NAB corepressors enhance activation by Egr transactivators. EMBO J. 1998;17:6010–6019.[Medline] [Order article via Infotrieve]
  37. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ III, Hill D, Haber DA. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993;90:5100–5104.[Abstract/Free Full Text]
  38. Jackson CL, Schwartz SM. Pharmacology of smooth muscle replication. Hypertension. 1992;20:713–736.[Abstract/Free Full Text]
  39. O'Brien ER, Schwartz SM. Update on the biology and clinical study of restenosis. Trends Cardiovasc Med. 1994;4:169–178.
  40. Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med. 1995;5:200–204.
  41. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–465.[Free Full Text]
  42. Schwartz SM, Reidy MA, O'Brien ERM. Assessment of factor important in atherosclerotic occlusion and restenosis. Thromb Haem. 1995;74:541–551.[Medline] [Order article via Infotrieve]
  43. Miano JM, Tota RR, Vlasic N, Danishefsky KJ, Stemerman MB. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol. 1990;137:761–765.[Abstract]
  44. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, Yulimura T, Miura K, Iwao H. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation. 1995;92:88–95.[Abstract/Free Full Text]
  45. Hultgardh-Nilsson A, Cercek B, Wang JW, Naito S, Lovdahl C, Sharifi B, Forrester JS, Fagin JA. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ Res. 1996;78:589–595.[Abstract/Free Full Text]
  46. Hu Y, Cheng L, Hochleitner B-W, Xu Q. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 1997;17:2808–2816.[Abstract/Free Full Text]
  47. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-{kappa}B and I{kappa}B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997;151:1085–1095.[Abstract]
  48. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem. 1995;270:5457–5461.[Abstract/Free Full Text]
  49. Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Hirakawa K, Yamamoto K. Expression of p53 protein and p53 gene transcripts in rabbit carotid arteries after balloon denudation. Histochem Cell Biol. 1997;107:365–370.[Medline] [Order article via Infotrieve]
  50. Wilson E, Vives F, Collins T, Ives HE. Strain-responsive regions in the platelet-derived growth factor-A gene promoter. Hypertension. 1998;31:170–175.[Abstract/Free Full Text]
  51. Lemstrom KB, Koskinen PK. Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation. 1997;96:1240–1249.[Abstract/Free Full Text]
  52. Hultgardh-Nilsson A, Lovdahl C, Blomgren K, Kallin B, Thyberg J. Expression of phenotype- and proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc Res. 1997;34:418–430.[Medline] [Order article via Infotrieve]
  53. Davies P, Patton W. Peripheral and central vascular smooth muscle cells from rat lung exhibit different cytoskeletal protein profiles but similar growth factor requirements. J Cell Physiol. 1994;159:399–406.[Medline] [Order article via Infotrieve]
  54. Calara F, Ameli S, Hultgardh-Nilsson A, Cercek B, Kupfer J, Hedin U, Forrester J, Shah PK, Nilsson J. Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells: potential role of FGF and PDGF. Arterioscler Thromb Vasc Biol. 1996;16:187–193.[Abstract/Free Full Text]
  55. Weaver AM, Owens GK, Gonias SL. Native and activated forms of {alpha}2-macroglobulin increase expression of platelet-derived growth factor {alpha}-receptor in vascular smooth muscle cells. Evidence for autocrine transforming growth factor-beta activity. J Biol Chem. 1995;270: 30741–30748.
  56. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF ß-receptors. J Cell Biol. 1994;125:917–928.[Abstract/Free Full Text]
  57. Eriksson A, Rorsman C, Ernlund A, Claesson-Welsh L, Heldin C-H. Ligand-induced homo- and hetero-dimerization of platelet-derived growth factor {alpha}- and ß-receptors in intact cells. Growth Factors. 1992;6:1–14.[Medline] [Order article via Infotrieve]
  58. Biesiada E, Razandi M, Levin ER. Egr-1 activates basic fibroblast growth factor transcription. J Biol Chem. 1996;271:18576–18581.[Abstract/Free Full Text]
  59. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1996;93:11831–11836.[Abstract/Free Full Text]
  60. Li L, Artlett CM, Jimenez SA, Hall DJ, Varga J. Positive regulation of human {alpha}1(I) collagen promoter activity by transcription factor Sp1. Gene. 1995;164:229–234.[Medline] [Order article via Infotrieve]
  61. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F. Sp1 is required for the early response of {alpha}2(I) collagen to transforming growth factor-ß1. J Biol Chem. 1997;272:19738–19745.[Abstract/Free Full Text]
  62. Thyberg J, Blomgren K, Hedin U, Dryjski M. Phenotypic modulation of smooth muscle cells during the formation of neointimal thickenings in the rat carotid artery after balloon injury: an electron-microscopic and stereological study. Cell Tissue Res. 1995;281:421–433.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
Y. Qin, E. M. Rezler, V. Gokhale, D. Sun, and L. H. Hurley
Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4
Nucleic Acids Res., December 3, 2007; 35(22): 7698 - 7713.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
J. Mallolas, O. Hurtado, M. Castellanos, M. Blanco, T. Sobrino, J. Serena, J. Vivancos, J. Castillo, I. Lizasoain, M. A. Moro, et al.
A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke
J. Exp. Med., March 20, 2006; 203(3): 711 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. R. Suriano, A. N. Sanford, N. Kim, M. Oh, S. Kennedy, M. J. Henderson, K. Dietzmann, and K. E. Sullivan
GCF2/LRRFIP1 Represses Tumor Necrosis Factor Alpha Expression
Mol. Cell. Biol., October 15, 2005; 25(20): 9073 - 9081.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
F. S. Santiago and L. M. Khachigian
Ets-1 Stimulates Platelet-Derived Growth Factor A-Chain Gene Transcription and Vascular Smooth Muscle Cell Growth via Cooperative Interactions With Sp1
Circ. Res., September 3, 2004; 95(5): 479 - 487.
[Abstract] [Full Text] [PDF]